Submissions from 2023
Sun exposure and associated risks in 17 countries: UK results, Thierry Passeron, Brigitte Dreno, Susana Puig, Chee L. Goh, Henry W. Lim, Fatimata Ly, Hee Y. Kang, and Akimichi Morita
43772 Sk(in depth): staying up-to-date with the latest dermatology research, Catherine Reilly, Raquel Hoopes, Nicole Trupiano, Kelly Young, Jenna Yousif, and Taylor Novice
42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up), Jonathan I. Silverberg, Mette Deleuran, Linda F. Stein Gold, Christopher G. Bunick, Dirk J. Hijnen, Brian M. Calimlim, Henrique D. Teixeira, and Andrew Middle Platt
Comparison of investigator global assessment (IGA) and patient's global assessment (ptGA) of acne vulgaris among patients with moderate-to-severe non-nodular acne vulgaris (AV) administered sarecycline in community practices across the US: Analysis of PROSES study results, Linda F. Stein Gold, Andrew F. Alexis, Julie C. Harper, Emmy Graber, Hilary Baldwin, Leon Kircik, James Del Rosso, Richard G. Fried, Evan A. Rieder, Adelaide Hebert, Siva Narayanan, Volker Koscielny, and Ismail Kasujee
40660 Clinically Meaningful Improvement on the Acne Quality of Life Following Treatment with IDP- 126 Gel for Moderate-to-Severe Acne: A Post Hoc Exploratory Pooled Analysis of Phase III Trial Data, Linda F. Stein Gold, Ankur A. Dashputre, May Kamleh, Danellys Borroto, Tina Lin, Gale Harding, and George Joseph
43374 Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne, Linda F. Stein Gold, Alexandra Golant, Rocco Serrao, Anna M. Tallman, and Philip M. Brown
Tapinarof cream 1% once daily for plaque psoriasis: improvements in quality of life and clinical efficacy in two pivotal Phase 3 trials, Linda F. Stein Gold, Christopher E. M Griffiths, Anna M. Tallman, Philip M. Brown, and Mark G. Lebwohl
Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: Randomized Phase 2 and Phase 3 studies of the first triple combination drug, Linda F. Stein Gold, Leon H. Kircik, Emil A. Tanghetti, Hilary Baldwin, Zoe D. Draelos, Michael Gold, Edward Lain, David M. Pariser, Neil Sadick, Radhakrishnan Pillai, and Varsha Bhatt
Tapinarof Cream 1% Once Daily for Plaque Psoriasis in Two Pivotal Phase 3 Trials: Minimal Systemic Exposure is Consistent With Adverse Event Profile, Linda F. Stein Gold, Mark G. Lebwohl, Philip M. Brown, David S. Rubenstein, Glenn Tabolt, John E. Jett, and Stephen C. Piscitelli
441 Mpox in persons living with HIV: Results from an international dermatologic registry, A. G. Strahan, J. E. Lubov, S. Prasad, C. G. Casas, G. Hruza, Henry W. Lim, L. E. French, and E. Freeman
Impact of secukinumab on the need for rescue surgical intervention in patients with moderate to severe hidradenitis suppurativa: Post-hoc analysis of week 16 data from sunshine and sunrise trials, Hessel H. Van der Zee, Jacek C. Szepietowski, Christopher Sayed, Philippe Guillem, Iltefat H. Hamzavi, Stephanie Goldberg, Clarice Field, Christine-Elke Ortmann, Iryna Lobach, Magdalena B. Wozniak, Angela Llobet-Martinez, Shoba Ravichandran, Teresa Bachhuber, and Falk G. Bechara
Efficacy and safety of lebrikizumab at 16 weeks: Pooled analyses from ADvocate1 and ADvocate2 phase III trials in patients with moderate-to-severe atopic dermatitis, Richard B. Warren, Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D. Irvine, Linda F. Stein Gold, Andrew Blauvelt, and Eric L. Simpson
EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16, Andreas Wollenberg, Richard B. Warren, Jonathan I. Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D. Irvine, Linda F. Stein Gold, and Andrew Blauvelt
Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes re-pigmentation of stable lesions in patients with active nonsegmental vitiligo: results from a phase 2b, randomized, placebocontrolled, dose-ranging study, Yuji Yamaguchi, Elena Peeva, Ronald Shore, George Han, Lori A. Cox, Anindita Banerjee, Diamant Thaci, Iltefat Hamzavi, Abigail Sloan, Anand K. Ganesan, and Khaled Ezzedine
Submissions from 2022
EVALUATION of 1064/650NM PICOSECOND LASER SYSTEM EFFICACY for REDUCTION of PERI-ORBITAL HYPERPIGMENTATION, Rawaa Almukhtar, Emily S. Carr, Douglas Wu, and Mitchel P. Goldman
34631 Do patients with vitiligo and health care professionals treating them recognize the burden in living with the disease in the United States? Findings from the VALIANT study, Kristen Bibeau, John E. Harris, Iltefat H. Hamzavi, Anouk Lindley, Christine LaFiura, and Khaled Ezzedine
Clinical Outcomes Associated With Melanocytic Lesions Assessed Via Ancillary Gene Expression Profiling (GEP), Wyatt Boothby-Shoemaker, Brittani Jones, Linna L. Guan, and Ben J. Friedman
32388 Demographic and socioeconomic factors drive disparate outcomes in mycosis fungoides, Connor R. Buechler, Ethan Sagher, and Aaron Tisack
32329 Assessing the utility of Fontana-Masson and MART-1 stains in evaluating skin pigmentary changes induced by ultraviolet radiation and visible light, Marissa Ceresnie, Indermeet Kohli, Ben J. Friedman, Henry W. Lim, and Iltefat H. Hamzavi
617 The impact of the spectral composition of long-wavelength ultraviolet A1 and visible light on cutaneous biologic effects, Marissa Ceresnie, Jalal Maghfour, K El Dairi, Iltefat H. Hamzavi, Henry W. Lim, and Indermeet Kohli
CLINICAL APPLICATIONS of LASERS in TRANSGENDER MEDICINE, Marissa S. Ceresnie, Brittani Jones, Jalal Maghfour, and David M. Ozog
Management of truncal acne with oral sarecycline: pooled results from two Phase 3 clinical trials, James Q. Del Rosso, Linda F. Stein Gold, Hilary Baldwin, Julie C. Harper, Joshua Zeichner, Sabine Obagi, Emmy Graber, and Xochitl Jimenez
542 Murine epidermis harbors functionally distinct langerhans cell subsets, Peter Dimitrion, Indra Adrianto, Yi Yao, Michael Pawlitz, Ian Loveless, and Hongmei Peng
34794 Long-term safety and disease control of ruxolitinib cream among Black or African American patients with atopic dermatitis: Pooled results from 2 phase 3 studies, Lawrence F. Eichenfield, Linda F. Stein Gold, Zelma C. Chiesa Fuxench, May E. Venturanza, Haobo Ren, and Kanwaljit K. Brar
275 Effects of ruxolitinib cream on sleep and quality of life over 52 weeks in black patients with atopic dermatitis, L. F. Eichenfield, Linda F. Stein Gold, K. K. Brar, Z. C. Chiesa Fuxench, J. I. Silverberg, M. E. Venturanza, H. Kallender, J. Gao, and E. Simpson
287 Effects of ruxolitinib cream on pruritus in black patients with atopic dermatitis, L. F. Eichenfield, Linda F. Stein Gold, K. K. Brar, Z. C. Chiesa Fuxench, J. I. Silverberg, M. E. Venturanza, H. Kallender, J. Gao, and J. C. Szepietowski
367 Googling acne: Analyzing ingredients and price of over the counter acne products, Kareem Elhage, Jonah Yousif, Michael Kwa, and Linda F. Stein Gold
33714 Palisaded neutrophilic and granulomatous dermatitis in the setting of SRSF2-mutated chronic myelomonocytic leukemia: Case report and review of the literature, Christina D. Enescu, Avni Patel, and Ben J. Friedman
Updates on the hidradenitis suppurativa from the USA, Iltefat H. Hamzavi
34612 Exploring the natural history of vitiligo in the United States: Findings from the VALIANT study, John E. Harris, Kristen Bibeau, Iltefat H. Hamzavi, Pearl Grimes, Anouk Lindley, Christine LaFiura, and Khaled Ezzedine
35224 Identifying a correlation between preceding trauma and development of dermatofibrosarcoma protuberans: A review of the literature, Brittani Jones, Jesse Veenstra, and David M. Ozog
633 Comparison of soluble proteins from skin sections of acne and TCA induced postinflammatory hyperpigmentation and erythema, N. Karaman-Jurukovska, Iltefat H. Hamzavi, Indermeet Kohli, C. Nicholson, and Tasneem F. Mohammad
Roflumilast cream significantly improves patient burden and work productivity in patients with psoriasis, Leon H. Kircik, Lorne Albrecht, Laura K. Ferris, Melinda Gooderham, H. Chih-ho Hong, Steven E. Kempers, Mark G. Lebwohl, and Vandana K. Madkan
34441 Keratoderma blenorrhagicum and balanitis circinata: Indicators of reactive arthritis, Dayoung Ko, Meredith Hengy, and Chauncey A. McHargue
623 Variations in in vivo visible light phototesting methodologies, Indermeet Kohli
35360 Recalcitrant pediatric bullous erythema multiforme responsive to oral tofacitinib, Sasank Konda, Nayha Shetty, and Jesse Y. Liu
Safety and efficacy of once-daily roflumilast cream 0.3%, a potent phosphodiesterase-4 inhibitor, for the treatment of psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 trials, Mark G. Lebwohl, Leon H. Kircik, Angela Y. Moore, Linda F. Stein Gold, James Del Rosso, Zoe D. Draelos, Melinda G. Gooderham, and Lawrence J. Green
31064 The Detroit Keloid Scale: A validated tool for rating keloids, Alexis B. Lyons, David M. Ozog, Henry W. Lim, Kate V. Viola, Lamont R. Jones, and Amy Tang
396 Characterizing inpatient hospitalizations for hidradenitis suppurativa and assessing the impact of outpatient dermatology care on hospitalizations, Jalal Maghfour, Vivian Liu, and Richard H. Huggins
35186 Exploring the association between frontal fibrosing alopecia sunscreen and moisturizers, Jalal Maghfour and Joshua Olson
33396 Nonuremic calciphylaxis precipitated by COVID 19 infection, Nathaniel Messenger, Christina Artz, and Pranita V. Rambhatla
33778 The impact and implications of COVID-19 on using scalp cooling therapy for prevention of chemotherapy-induced alopecia, Taylor Novice, Madison Novice, Katerina Svigos, Molly Powers, and Kristen Lo Sicco
34722 Nail-patella syndrome: An early dermatologic diagnosis, Sandra Oska, Kelly Kennelly, and Vinod Misra
32622 Imaging technologies for presurgical margin assessment of basal cell carcinoma, Krishan Parashar, Angeli E. Torres, and Wyatt T. Boothby-Shoemaker
A pooled analysis of randomized, controlled, Phase 3 trials investigating the efficacy and safety of a novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis, Andreas Pinter, Lawrence J. Green, Johan Selmer, Morten Praestegaard, Linda F. Stein Gold, and Matthias Augustin
168 COVID-19 mRNA vaccine booster cutaneous reactions reported to the AAD/ILDS dermatology registry, S. Prasad, D. E. McMahon, A. Tyagi, R. Singh, R. Ali, Henry W. Lim, L. P. Fox, K. Blumenthal, G. Hruza, L. E. French, and E. Freeman
32131 Updating the relative risk of ultraviolet exposure and melanoma in fair skin types: A systematic review, Manisha Ravi, Michael Kwa, Kriti Babu, and Henry W. Lim
Differences in patient and dermatologist perspectives on psoriasis treatment: results from the UPLIFT survey, Kristian Reich, Paolo Gisondi, Linda F. Stein Gold, Peter van de Kerkhof, Richard Langley, Carle Paul, Lluis Puig, and Hideshi Torii
303 Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients With Vitiligo, David Rosmarin, Amit G. Pandya, Pearl Grimes, Mark G. Lebwohl, Alice B. Gottlieb, Iltefat Hamzavi, Kathleen Butler, and S. Wei
081 Modulation of the aryl hydrocarbon receptor by adipose tissue: Implications for skin carcinogenesis, S. Shareef, Jesse Veenstra, and J. J. Bernard
35180 “Could I be allergic to my new hidradenitis suppurativa Medication?” Characterization of a cutaneous delayed-type drug hypersensitivity reaction to secukinumab, Nayha Shetty, Sasank Konda, and Jesse Veenstra
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials, Jonathan I. Silverberg, Diamant Thaçi, Julien Seneschal, Linda F. Stein Gold, Andrew Blauvelt, Eric Simpson, Chia-Yu Chu, Zhuqing T. Liu, Renata Gontijo Lima, Sreekumar Pillai, and Emma Guttman-Yassky
34587 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: Pooled analysis from two randomized phase 3 studies, Eric L. Simpson, Robert Bissonnette, and Linda F. Stein Gold
34039 Maintenance of skin clearance in a long-term open-label study of fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in participants with prior use of topical treatments, Linda F. Stein Gold, Javier Alonso-Llamazares, and Joshua Zeichner
33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area, Linda F. Stein Gold, Jerry Bagel, James Del Rosso, Lawrence J. Green, Mark Lebwohl, Leon H. Kircik, Amy Feng, Scott Snyder, Robert C. Higham, Patrick Burnett, and David R. Berk
34613 Tapinarof cream 1% once daily (QD) for plaque psoriasis: Secondary efficacy outcomes from a long-term extension (LTE) trial, Linda F. Stein Gold, Benjamin Ehst, Laura K. Ferris, Philip M. Brown, David S. Rubenstein, Anna M. Tallman, and Jerry Bagel
33731 Use of digital resource centers for atopic dermatitis patients, caregivers, and health care professionals to improve shared decision-making and proactive management, Linda F. Stein Gold, Adam J. Friedman, and Kanwaljit Brar
Rapid and clinically meaningful improvement of plaque psoriasis-associated itch after treatment with calcipotriol and betamethasone dipropionate cream, Linda F. Stein Gold, Lawrence J. Green, Sunil Dhawan, Astrid Kirsch, Johan Selmer, and Morten Præstegaard
32970 Efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: Randomized phase 2 and phase 3 studies of the first triple-combination drug, Linda F. Stein Gold, Leon H. Kircik, and Emil A. Tanghetti
Improvement in psoriasis symptoms and involvement in special areas: 32-week results from advance, Linda F. Stein Gold, Kim Papp, David Pariser, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, and Mindy Chen
Improvement in patient- and physician-reported outcomes with apremilast treatment in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial: Analyses by baseline BSA and PASI, Linda F. Stein Gold, Kim Papp, David Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, and Melinda Gooderham
33354 Efficacy of apremilast in patients with mild to moderate psoriasis assessed by the physician global assessment and body surface area composite tool: Post hoc analysis from ADVANCE, Linda F. Stein Gold, Kim Papp, David Pariser, Howard Sofen, Mindy Chen, Sue Cheng, Hernan Picard, Yuri Klyachkin, and Lawrence Green
Impact of crisaborole in patients with mild-to-moderate atopic dermatitis who received prior treatment, Linda F. Stein Gold, Vivian Shi, Bonnie Vlahos, Paul Sanders, Chuanbo Zang, and Amy Cha
33356 A multinational chart review to examine gastrointestinal symptoms and their management in patients treated with apremilast for plaque psoriasis, Linda F. Stein Gold, Edward Tuttle, Wendy Y. Cheng, Rose Chang, Catherine Nguyen, Louise H. Yu, Anne Bouloc, Yuri Klyachkin, Tara Nazareth, and Denis Jullien
Tapinarof cream 1% once daily for plaque psoriasis: long-term extension trial of a novel therapeutic aryl hydrocarbon receptor modulating agent, Bruce Strober, Linda F. Stein Gold, Robert Bissonnette, April Armstrong, Andrew Blauvelt, Leon Kircik, Philip Brown, and Anna Tallman
359 Public sunscreen dispenser distribution in the United States: Continued COVID-19 trends during 2021, M. D. Szeto, R. Kokoska, Jalal Maghfour, C. Rundle, C. Presley, T. Harp, A. Hamp, V. Wegener, J. Hugh, and R. Dellavalle
33111 New onset scrotal lesions in a patient with herpes simplex virus treated with foscarnet, Rebecca F. Wang and Ben J. Friedman
34745 US and EU sunscreens: A review of ultraviolet (UV) filters and safety data, Nikita Wong, Milan N. Pantelic, and Michael Kwa
USE of OPTICAL COHERENCE TOMOGRAPHY and REFLECTANCE CONFOCAL MICROSCOPY to GUIDE TREATMENT MARGINS of BASAL CELL CARCINOMA, John Wuennenberg, David M. Ozog, Indermeet Kohli, and Brittani Jones
Proactive Management with Cal/BD Foam in Patients with Plaque Psoriasis prolongs Time with improved health-related Quality of Life when compared with reactive Management, Elisabeth Wurzer, Linda F. Stein Gold, Ahmad Jalili, Henrik Thoning, and Piergiacomo Calzavara-Pinton
ANALYSIS by OCT of PRE/POST LP 1064NM LASER TREATMENT of SUPERFICIAL and NODULAR BCCS, Christopher B. Zachary, John Soliman, Jon Holmes, David M. Ozog, John Wuennenberg, Wyatt Boothby-Shoemaker, Erica Baugh, and Indermeet Kohli
A randomized, double-blind, vehiclecontrolled Phase 2a study evaluating once daily roflumilast foam 0.3% in patients with moderate to severe seborrheic dermatitis, Matthew Zirwas, Zoe D. Draelos, Janet Dubois, Leon Kircik, Angela Y. Moore, Linda F. Stein Gold, Javier Alonso-Llamazares, and Michael Bukhalo
Submissions from 2021
A case of salivary gland hyalinizing clear cell carcinoma (HCCC) with cutaneous metastasis, Rand Abou Shaar, Sheeren Zia, Mohamed Alhamar, and Ben J. Friedman
A randomized, placebo-controlled, phase 2 study of the Janus Kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa, Afsaneh Alavi, Iltefat Hamzavi, Kurt Brown, Leandro L. Santos, Zhaoyin Zhu, Michael D. Howell, and Joslyn Kirby
27630 Assessing signs and symptoms of hidradenitis suppurativa from the patient perspective, aFSANEH Alavi, Iltefat H. Hamzavi, Sarah Baradaran, Susan D. Mathias, Hilary H. Colwell, Michael Song, and Chenglong Han
28353 Hemorrhagic cellulitis secondary to vibrio fluvialis infection, Harleen Arora and Chauncey A. McHargue
Correlation of PD-L1 expression, clinicopathologic and molecular characteristics in an array of solid tumors: A large-scale real world study, Kanika Arora, Harshita Mehrotra, Kasturi Saikia, Rand Abou Shaar, Mohamed Alhamar, and Dhananjay A. Chitale
Development and validation of facial vitiligo area scoring index (F-VASI) using the fingertip unit, Jung Min Bae, Raheel Zubair, Hyun Jeong Ju, Indermeet Kohli, Han Na Lee, S H. Eun, Alexis B. Lyons, Gautham Vellaichamy, Tae Young Han, Henry W. Lim, and Iltefat Hamzavi
PRO65 Engaging Patients in Drug Development for Regulatory and HTA Decisions: A Case Study in Patients with Hidradenitis Suppurativa, S Baradaran, S D. Mathias, H H. Colwell, A Alavi, Iltefat H. Hamzavi, M Song, R Villacorta, R Slowik, N Li, and C Han
26856 Proliferative nodule resembling angiomatoid Spitz with pronounced degenerative atypia arising within a giant congenital nevus, Taylor Braunberger, M Adelman, Tor Shwayder, L E. Clarke, and Ben J. Friedman
26843 Carbon dioxide laser excision for hidradenitis suppurativa patients—Healing, complications, and recurrence in patients with diabetes mellitus and history of smoking, Taylor Braunberger, P Vakharia, Nneamaka Ezekwe, Cynthia L. Nicholson, Angela Parks-Miller, and Iltefat H. Hamzavi
222 Whole-blood immune profile in hidradenitis suppurativa, Peter Dimitrion, Congcong Yin, Kalpana Subedi, Namir Khalasawi, Yi Yao, Angie Parks-Miller, Jesse Veenstra, Gautham Vellaichamy, Henry W. Lim, Iltefat Hamzavi, Li Zhou, and Qing-Sheng Mi
28043 Roflumilast cream significantly improves chronic plaque psoriasis in patients with steroid-sensitive area involvement, Zoe Draelos, Mark G. Lebwohl, Charles W. Lynde, Walter K. Nahm, Kim A. Papp, David M. Pariser, Linda F. Stein Gold, Daniel Stewart, Robert C. Higham, Lynn Navale, and David R. Berk
Roflumilast Cream Significantly Improves Chronic Plaque Psoriasis in Patients with Steroid-Sensitive Area Involvement, Zoe D. Drealos, Mark G. Lebwohl, Charles W. Lynde, Walter K. Nahm, Kim A. Papp, David Middle Pariser, Linda F. Stein Gold, and Daniel Stewart
26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial, K C. Duffin, Linda F. Stein Gold, Craig Leonardi, David Pariser, Lawrence Green, Howard Sofen, Bruce Strober, Mindy Chen, Yao Wang, and Kim Papp
26914 Ustekinumab-induced myositis: A case series, Nneamaka Ezekwe, J Smith, Aunna Pourang, and Iltefat H. Hamzavi
Improvement in patient global impression measures with upadacitinib with or without topical corticosteroids in moderate to severe atopic dermatitis: Results from placebo-controlled phase 3 studies, M Gooderham, M Deleuran, Linda F. Stein Gold, B Calimlim, J Zeng, S Takemoto, E Raymundo, and S Weidinger
LB756 Patient-reported outcomes for sarecycline effectiveness in Acne Vulgaris in real-world settings: PROSES study protocol, E Graber, H Baldwin, J Harper, A Alexis, Linda F. Stein Gold, A Herbert, R Fried, E Rieder, L Kircik, J Del Rosso, I Kasujee, and A Grada
28666 Global initiatives in dermatology and education, C Grayson, Olabola Awosika, and E Pritchett
25486 Correlation of the Vitiligo Area Scoring Index with patient- and physician-reported measures of clinical improvement in a randomized, double-blind phase 2 study, Iltefat H. Hamzavi, David Rosmarin, Kathleen Butler, Fiona Kuo, Zhaoyin Zhu, and Kang Sun
A Diversity outbred (DO) mouse model reveals regulators of HER2-driven tumorigenesis, Jennifer Jacob, Kuang Wei, Joyce D. Reyes, Congcong Yin, Elizabeth Rondini, Qing-Sheng Mi, James Granneman, and Prahlad Parajuli
27099 Actinomyces infection within red pigment of a tattoo, Angela J. Jiang and Holly Kerr
28139 A case of IgA vasculitis associated with underlying cytomegalovirus colitis, Katelyn M. Kim and Ben J. Friedman
28367 A case of chronic prurigo nodularis, angiolymphoid hyperplasia with eosinophilia, and reactive lymphadenopathy: Intersection of multiple processes, or a novel clinical entity?, Elena Kurland, Bridget Myers, Ben J. Friedman, and Pranita V. Rambhatla
LB762 Initiation patterns among novel systemic agents for U.S. adults with Psoriasis and Psoriatic Arthritis, Michael Kwa, R Kang, M Cherupally, C Aikman, and R Ackermann
Roflumilast Cream, a Once-daily, Potent Phosphodiesterase-4 Inhibitor, in Chronic Plaque Psoriasis Patients: Efficacy and Safety from DERMIS-1 and DERMIS-2 Phase 3 Trials, Mark G. Lebwohl, Leon H. Kircik, Angela Y. Moore, Linda F. Stein Gold, Zoe D. Draelos, Melinda G. Gooderham, Kim A. Papp, and Jerry Bagel
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: Results from the open-label run-in period of JADE REGIMEN, Mark G. Lebwohl, Margitta Worm, Linda F. Stein Gold, Christine Bangert, Peter Schmid-Grendelmeier, Tahira Khan, Pinaki Biswas, Marco DiBonaventura, Gary Chan, Ketti Terry, Hernan Valdez, and Claire Clibborn
28545 A man with halo nevi and premature hair graying, Alexis B. Lyons, Olabola Awosika, and Henry W. Lim
27636 Addition of narrow-band ultraviolet light B phototherapy to ruxolitinib cream in patients with vitiligo, Amit G. Pandya, John E. Harris, Mark Lebwohl, Iltefat H. Hamzavi, Kathleen Butler, Fiona Kuo, Shaoceng Wei, and David Rosmarin
25602 Improvements and response achievement in PASI subscale domains for head scaling and erythema in apremilast-treated patients with moderate to severe plaque psoriasis of the scalp: Results from the STYLE study, Kim Papp, Abby Van Voorhees, Linda F. Stein Gold, Mark Lebwohl, Bruce Strober, Zuoshun Zhang, and Yao Wang
